Technetium-99m-MIBI Versus Fluorine-18-FDG in Diffuse Multiple Myeloma

Experience of scintigraphic detection of bone lesion and active bone marrow involvement of multiple myeloma, especially with sestamibi and FDG-PET scans is in evolution. We report a case of intense sestamibi uptake in bone marrow correlating with the extent of the disease, while FDG-PET scans showed activity only in areas of active disease progression associated with pain. Technetium-99m-sestamibi appears to indicate the extent of the disease, while[18F]FDG-PET scans show sites of active tumor proliferation and may be useful in directing local therapy such as radiation. Key Words: multiple myeloma; sestamibi; fluorine-18-FDG; PET J NucÃ-Med 1997; 38:1208-1210 Äeveral radiopharmaceuticals have been used for detection of bone involvement in patients with multiple myeloma (1,2). Bone scintigraphy with 99mTc-MDP is relatively insensitive when compared with conventional radiographs (3,4). Experi ence with 99mTc-sestamibi and [IKF]FDG, both well-know